China Resources Pharmaceutical Group Limited (Stock Code: 3320) announced that its subsidiary, KPC Pharmaceuticals, Inc. (listed on the Shanghai Stock Exchange), released unaudited financial results for the nine months ended 30 September 2025. KPC recorded revenue of RMB4.75 billion, compared with RMB5.80 billion for the same period in 2024, and net profit of RMB323.40 million, compared with RMB503.43 million in the prior year. During the period, KPC reported a net decrease in cash and cash equivalents of RMB1.41 billion, ending the third quarter with a balance of RMB722.11 million.

As of 30 September 2025, KPC’s total assets stood at RMB12.01 billion, total liabilities at RMB5.15 billion, and owners’ equity at RMB6.86 billion. These figures were compiled under the PRC Generally Accepted Accounting Principles and have not been reviewed or audited by the Company’s auditors. The published data reflect KPC’s standalone financial position and do not represent the entire Group’s status. Readers are advised to refer to KPC’s quarterly report on the Shanghai Stock Exchange website for further details and exercise caution when interpreting the information.